Hideya Kitamura

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8–mediated activation of TGF-β

Hideya Kitamura, Stephanie Cambier, Sangeeta Somanath et al. · Journal of Clinical Investigation · 2011 · 191 citations

Asthma, Inflammatory Lung Disease, Lung Inflammation +22

Distinct Characteristics of Pleuroparenchymal Fibroelastosis With Usual Interstitial Pneumonia Compared With Idiopathic Pulmonary Fibrosis

T. Oda, Takashi Ogura, Hideya Kitamura et al. · CHEST Journal · 2014 · 136 citations

Pleuroparenchymal Fibroelastosis, Distinct Characteristics, Idiopathic Pulmonary Fibrosis +5

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

Toby M. Maher, Susanne Stowasser, Yasuhiko Nishioka et al. · The Lancet Respiratory Medicine · 2019 · 96 citations · Full text

Fibrosis, Extracellular Matrix Turnover, Inflammatory Lung Disease +7

Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice

Ryo Okuda, Eri Hagiwara, Tomohisa Baba et al. · Respiratory Medicine · 2013 · 95 citations

Antifibrotic Therapy, Fibrosis, Advanced Lung Disease +8